Several studies have demonstrated increased inflammatory activity and bone resorption in CF patients, with evidence of elevated serum levels of inflammatory markers, such as TNF-α, Interleukin-1β (IL-1β) and IL-6, and bone resorption markers, such as RANKL [37,38,39]. This evidence concerns the gene IL6 and cystic fibrosis.